Abstract
Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010. We describe the epidemiology and clinical features of the adverse events and explore the biological basis for the adverse events using an in vitro model.
| Original language | English |
|---|---|
| Pages (from-to) | 5107-5113 |
| Number of pages | 7 |
| Journal | Vaccine |
| Volume | 29 |
| Issue number | 32 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint Dive into the research topics of 'Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms'. Together they form a unique fingerprint.
Cite this
Blyth, C. C., Currie, A. J., Wiertsema, S. P., Conway, N., Kirkham, L. A. S., Fuery, A., Mascaro, F., Geelhoed, G. C., & Richmond, P. C. (2011). Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine, 29(32), 5107-5113. https://doi.org/10.1016/j.vaccine.2011.05.054